BiomX Inc. (PHGE): Entry into a Material Definitive Agreement
BiomX Inc. (PHGE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea030154401ex10-1.htm SHARE PURCHASE AND OPTION AGREEMENT DATED AUGUST 5, 2026 BETWEEN BIOMX INC. AND MAYERS VENTURES LLC Exhibit 10.1 SHARE PURCHASE AND OPTION AGREEMENT (M.E.A. Testing Systems Ltd. Equity) This Share Purchase and Option Agreement (this “Agreement”) is
How this was made
The 30-second read
Why it matters
The agreement gives BiomX an initial 10% stake via a secondary share purchase and an exclusive option to acquire the remaining holdings through June 30, 2028, with option pricing determined at BiomX’s discretion using 2027 Net Revenue (2x) or EBITDA (4x) from audited financial statements.
Market read
Traders should focus on deal execution milestones (NYSE American listing approval, lien release/subordination, and diligence confirmations) and how the option valuation formula could affect perceived upside.
What to watch
Key risks include the need for NYSE American approval of the supplemental listing application, confirmation of lien status with Bank Hapoalim, and diligence on technology ownership and customer relationships (e.g., IAI and Elbit).
Background
The filing is an SEC Form 8-K reporting entry into a Share Purchase and Option Agreement dated Aug 5, 2026 between BiomX Inc. and Mayers Ventures LLC, involving M.E.A. Testing Systems Ltd. and related MEA Motomova India.
Ticker impact
BiomX (PHGE) entered a material share purchase and option agreement to buy 10% of MEA Companies and obtain an option for the rest through June 30, 2028.
Near-term volatility risk around deal terms, NYSE American listing approval for restricted shares, and diligence outcomes; direction depends on market view of MEA technology and the option valuation mechanics.
This is a primary SEC filing with concrete deal structure (10% purchase plus option, option pricing formula, and NYSE American approval condition), but the excerpt does not include deal economics beyond the $50k cash and restricted-share consideration, nor any confirmed financial performance of MEA.
Market effects
Could signal continued M&A-style consolidation or technology licensing in drone-related testing, but the excerpt is too narrow for broad sector read-through.
MEA is an Israeli private company; any follow-on approvals or diligence outcomes could affect related Israel defense-tech supply chains, but impact is likely company-specific.
Limited global relevance from the excerpt alone; the deal is structured around 2027 financial metrics and NYSE listing approval rather than immediate global demand shifts.
Counterpoint
The option price is based on 2027 Net Revenue or EBITDA, so the economics may be less favorable if MEA’s 2027 performance underwhelms, making the deal more contingent than it appears.
Key entities
- public_companyBiomX Inc.
NYSE American-listed purchaser entering the share purchase and option agreement (PHGE).
- counterpartyMayers Ventures LLC
Seller granting the purchase and exclusive option rights to BiomX.
- private_companyM.E.A. Testing Systems Ltd. (MEA)
Israeli private company whose shares and technology rights are the subject of the transaction.
- private_or_otc_companyMotomova Inc.
Holds the majority of MEA ordinary and preferred shares and is the vehicle whose remaining holdings are covered by the option.
- lien_holderBank Hapoalim
First-priority lien holder over MEA assets, subject to confirmation and potential release/subordination.
